Sangamo Therapeutics, Inc. and Chroma Medicine, Inc. announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world's largest library of ZFPs, deploying them to address numerous therapeutically relevant targets. Advancing the transformative potential of epigenetic editing, Chroma is expanding the versatility of its platform by leveraging Sangamo's ZFPs.

Following a research evaluation period, Chroma has the option to license the ZFPs for potential worldwide development and commercialization of epigenetic medicines for certain therapeutic targets. Under the terms of the agreement, Chroma will evaluate novel Sangamo ZFPs for specified collaboration targets outside of the central nervous system in exchange for an upfront technology access payment. If Chroma exercises its option for any or all targets, Sangamo would be eligible to receive an option exercise payment, in addition to potential development and commercial milestone payments, as well as royalties on any Chroma products incorporating the licensed ZFPs.

Chroma will lead and fund all research, development, manufacture, and commercialization of products incorporating the licensed Sangamo ZFPs.